Review

Histone lysine methyltransferases as anti-cancer targets for drug discovery

Qing LIU1,2,3, Ming-wei WANG1,2,3,*

1The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; 2The National Center for Drug Screening, Shanghai 201203, China; 3School of Pharmacy, Fudan University, Shanghai 201203, China

Post-translational epigenetic modification of histones is controlled by a number of histone-modifying enzymes. Such modification regulates the accessibility of DNA and the subsequent expression or silencing of a gene. Human histone methyltransferases (HMTs) constitute a large family that includes histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs). There is increasing evidence showing a correlation between HKMTs and cancer pathogenesis. Here, we present an overview of representative HKMTs, including their biological and biochemical properties as well as the profiles of small molecule inhibitors for a comprehensive understanding of HKMTs in drug discovery.

Keywords: histone methyltransferases; adenosylmethionine; small molecule inhibitors; anti-cancer drugs; epigenetic modification; drug discovery

Acta Pharmacologica Sinica (2016) 37: 1273–1280; doi: 10.1038/aps.2016.64; published online 11 Jul 2016

Introduction

Post-translational epigenetic modifications of histones are controlled by histone-modifying enzymes, including histone methyltransferases (HMTs), histone demethylases, histone acetyltransferases, histone deacetylases (HDACs), ubiquitin ligases, and other specific kinases phosphorylating serine residues on histones. Such modifications regulate the accessibility of DNA and the subsequent expression or silencing of a gene[1, 2]. Histone methyltransferases include a large family of dozens of histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs), many of which have been found to play critical roles in cell differentiation, gene regulation, DNA recombination and damage repair[3–6].

The methylation of histone lysine residues was first discovered in the 1960s[7, 8] and was believed to be irreversible in the following decades until the discovery of a lysine demethylase in 2004[9]. Recently, increasing evidence indicating a correlation between HKMTs and cancer pathogenesis has emerged[3–8]. Therefore, a number of small molecule inhibitors of histone lysine methyltransferases have been identified and exhibited selective cancer cell killing activities in vitro and in vivo, suggesting the possibility of using HKMTs as targets for cancer therapy. Here, we discuss individual histone lysine methylation with the currently available small molecule inhibitors and their applications in cancer treatment.

HKMTs-catalyzed methylation

Histone lysine methyltransferases (HKMTs) transfer the methyl group from the cofactor adenosylmethionine (AdoMet), which contains a highly reactive methylthiol group, to the tailed nitrogen of the substrate lysine residue, producing mono-, di-, or tri-methylated products and its analogue adenosylhomocysteine (AdoHcy) (Figure 1)[10, 11]. AdoHcy is structurally similar to AdoMet, binding to methyltransferases in the same orientation with a similar $K_d$ value, but it lacks the reactive methyl group and acts as a competitive inhibitor with respect to AdoMet[12]. Additionally, it cannot be used as a probe in cell biology or in vivo because of its quick degradation to adenosine and homocysteine by SAH hydrolase[13].

Catalytic active sites in HKMTs

Two pockets are involved in the catalytic active sites: a SAM-binding pocket and a lysine acceptor channel, which are on opposite sides of the protein surface facilitating the entrance of two substrates to the active sites from opposite sides of the enzyme surface[14]. The structures of cofactor binding sites are conserved in different SAM-dependent methyltransfer-
Methylation of lysine residues by histone methyltransferases utilizing adenosylmethionine (AdoMet) as a cofactor.

Representative HKMTs and their inhibitors

DOT1L, the only HKMT belonging to class I methyltransferases, mono-, di-, and tri-methylates H3K79 and plays a role in embryonic development and hematopoiesis, etc. Compared with many other SET-domain HKMTs, DOT1L is a distributive enzyme, which releases SAH, and mono-, di- and tri-methylated products at the same time after one catalytic cycle. Several studies indicated DOT1L as a target for acute leukemia with MLL (mixed-lineage leukemia) gene translocations. MLL rearrangements result in the loss of the SET-domain H3K4 methyltransferase on the carboxy terminal, and the remaining amino-terminal MLL protein is fused to one of more than 60 different partner genes (predominantly, AF4, AF9, AF10, and ENL), which is found to recruit DOT1L as a part of transcription protein complexes and subsequently methylates H3K79 instead of H3K4. Such an aberrant epigenetic modification leads to the overexpression of MLL-target genes such as HOXA9 and MEIS1 and causes leukemia. Therefore, DOT1L is proposed as a target for the therapeutic intervention of MLL-rearranged leukemia. Several potent small molecules have thus been developed including SAH-like scaffold, iodoethyl-containing scaffold, urea or benzoimidazole-containing scaffold. Among them, two inhibitors (EPZ004777 and EPZ5676) disclosed by Epizyme bearing urea or benzoimidazole group substituted on the side chain of the aminonucleoside were identified as SAM-competitive DOT1L selective inhibitors with high potencies (IC₅₀=0.4 nmol/L for EPZ004777 and Kᵢ=0.08 nmol/L for EPZ5676, respectively) (Table 1). They dose-dependently inhibited global H3K79 levels in MLL-rearranged leukemia cells, transcript levels of MLL fusion target genes such as HOXA9 and MEIS1, and the proliferation of MLL-rearranged leukemia cells, with little or no effect on non-MLL-rearranged leukemia cells. However, the poor pharmacokinetic properties (short half-life, etc) of these two compounds limited their conventional dosing in vivo, and they are used with a subcutaneously implanted mini-osmotic pump instead.

EHMT1/2

Euchromatin histone methyltransferases (EHMTs), including G9a encoded by EHMT2 and GLP (G9a-like protein) encoded by EHMT1, are an evolutionarily conserved protein family, which mono- or di-methylate H3K9 as well as other non-histone substrates such as K373 of the tumor suppressor p53. EHMTs regulate transcriptional repression and activation in the form of a heterodimeric complex in the process of germ cell formation, embryogenesis and cardiac morphogenesis. G9a is highly expressed in a variety of human cancers with a poor prognosis such as leukemia, prostate cancer, lung cancer, and hepatocellular carcinoma. Reduction of G9a expression levels inhibited lung and breast cancer cell proliferation, migration and invasion in vitro and suppressed primary tumor growth and metastasis in vivo. Renneville et al demonstrated in 2015 that knockdown of either EHMT1 or EHMT2 could significantly increase the expression of γ-globin genes, and the percentage of cells expressing hemoglobin F (HbF). This discovery may lead to a new therapy for sickle cell anemia.

Figure 1. Methylation of lysine residues by histone methyltransferases utilizing adenosylmethionine (AdoMet) as a cofactor.
Table 1. The profiles of small molecule inhibitors of histone lysine methyltransferases (HKMTs).

| Compound     | Target HKMTs | Mechanism          | Biochemical potency (IC₅₀) | Cellular potency (IC₅₀) | In vivo Fold potency | Status            | Reference |
|--------------|--------------|--------------------|----------------------------|-------------------------|----------------------|---------------------|-----------|
| BIX-01294    | EHMTs        | Substrate competitive | 1.9±0.1 μmol/L (EHMT2) | 500±43 nmol/L (MDA-MB-231) | No                   | No inhibition observed | Preclinical | 31, 32, 33 |
| UNC0638      | EHMTs        | Substrate competitive | <15 nmol/L (EHMT2)      | 81±9 nmol/L (MDA-MB-231) | No                  | ~500 (other HMTs)   | Biological   | 30, 33    |
| UNC0646      | EHMTs        | Substrate competitive | 0.006 μmol/L (EHMT2)  | 0.026 μmol/L (MDA-MB-231) | No                  | No report           | Biological   | 34        |
| UNC0631      | EHMTs        | Unknown            | 1.6 μmol/L (EHMT2)     | No                      | ~100 (other 3 HMTs) | Biological testing  | 35        |
| Cpd 4d       | EZH2         | SAM competitive    | 54±5 nmol/L (EZH2-PRC2) | 80±30 nmol/L (OCI-LY19 EZH2<sup>WT</sup>) | No | ~50 (EZH1) >500 (other 15 HMTs) | Preclinical | 40        |
| EPZ05687     | EZH2         | SAM competitive    | 11±5 nmol/L (EZH2)     | 8 nmol/L (OCI-LY19, EZH2<sup>WT</sup>) | No | ~35 (EZH1) >4500 (other HMTs) | Phase II    | 51        |

(To be continued)
| Compound | Target HKMTs | Mechanism | Biochemical potency (IC_{50}) | Cellular potency (IC_{50}) | In vivo activity | Fold selectivity | Status | Reference |
|----------|--------------|-----------|-------------------------------|---------------------------|-------------------|-----------------|---------|-----------|
|          | EZH2         | SAM       | 9.9 nmol/L (EZH2)             | 28–861 nmol/L (DLBCL, EZH2 mutants) | Yes               | −150 (EZH1) −1000 (other 20 HMTs) | Phase I | 49        |
|          |              | competitive |                               |                           |                   |                 |         |           |
|          | EZH2         | SAM       | 4 nmol/L (EZH2)               | 174±84 nmol/L (HCC1806)   | No                | −60 (EZH1) −1000 (other HMTs) | Preclinical | 48        |
|          |              | competitive |                               |                           |                   |                 |         |           |
|          | EZH2         | SAM       | 15±2 nmol/L (EZH2<sup>WT</sup>) 13±3 nmol/L (EZH2<sup>Y641F</sup>) | −370 nmol/L (SU-DHL6, EZH2<sup>Y641F</sup>) | No                | −90 (EZH1) >1000 (other HMTs) | Biological testing | 50        |
|          |              | competitive |                               |                           |                   |                 |         |           |
|          | EZH2         | SAM       | <10 nmol/L (EZH2)             | 124±11 nmol/L (MCF10A, EZH2<sup>WT</sup>) | Yes               | −10 (EZH1) −10000 (other HMTs) | Preclinical | 47        |
|          |              | competitive |                               |                           |                   |                 |         |           |
|          | DOT1L        | SAM       | 38 nmol/L (Cpd 4) 120 nmol/L (Cpd 5) 110 nmol/L (Cpd 6) | No | No | >29 (other 4 HMTs) | Biological testing | 21        |
|          |              | competitive |                               |                           |                   |                 |         |           |
|          | DOT1L        | SAM       | 0.4±0.1 nmol/L (MLL-rearranged leukemia cell lines) | 0.17–6.47 μmol/L | Yes | >1000 (other HMTs) | Preclinical | 22        |

(To be continued)
cell disease (SCD) because induction of HbF is a well-validated strategy, and novel epigenetic regulators such as HbF inducers are attractive targets for SCD treatment.

BIX01294, identified through a high-throughput screening, was the first reported\cite{31, 32} selective small molecule inhibitor of G9a and GLP, showing an IC\textsubscript{50} of 1.9 µmol/L for G9a and 0.7 µmol/L for GLP, separately. The crystal structure of GLP with SAH and BIX01294 demonstrated that BIX01294 did not bind to the SAM binding pocket but was in a substrate groove that was usually occupied by residues H3K4-H3R8 at the N-terminal of the target H3K9. The structure of BIX01294 consists of three parts: quinazoline, piperidine and diazepane subunits. Further structure-activity relationship (SAR) studies were conducted, including the extension of 7-methoxy into the target lysine binding channel and replacement of the benzyl group on the piperidine, represented by UNC0638\cite{30, 33}, UNC0646\cite{34} and UNC0631\cite{34}. All three compounds showed high potency both in a fluorescence-based SAH-coupled assay (IC\textsubscript{50}: 4–19 nmol/L) and in the H3K9me2 In-Cell Western (ICW) assay (IC\textsubscript{50}: 25–81 nmol/L), with an excellent toxicity to function ratio range of 110–140 in MDA-MB-231 (breast carcinoma) cells compared with BIX01294 (<6). UNC0638 could also dose-dependently increase human γ-globin expression, HbF expression, and mouse embryonic γ-globin gene expression without altering the cellular morphology at a concentration up to 0.25 µmol/L and without affecting cell proliferation and viability up to 0.1 µmol/L in primary adult human erythroid cells \textit{ex vivo}. A combination of UNC0638 with entinostat (HDAC inhibitor) or decitabine (inhibitor of DNA methyltransferase) additively increased the gene expression of γ-globin, suggesting a different γ-globin inducing mechanism of EHMT1/2 inhibition in comparison to entinostat or decitabine\cite{30}. Our group\cite{35} has also reported a group of sinefungin analogues which dose-dependently inhibited EHMT1/2 with an IC\textsubscript{50} of 1.5–1.6 µmol/L. However, it was not competitive with SAM or substrate, which is indicative of other binding sites in EHMT1/2.

**EZH2 and PRC2**

The polycomb repressive complex 2 (PRC2), which is responsible for mono-, di-, and tri-methylation of H3K27, is composed of EED (embryonic ectoderm development), SUZ12, RbAp48 and an enzymatic subunit of either EZH2 (enhancer of zeste homologue 2, also known as KMT6 or KMT6A) or its homolog EZH1 (enhancer of zeste homologue 1, also known as KMT6B), which shares 96% sequence identity in the SET
domains with EZH2[36]. EZH2 overexpression is implicated in several tumor types correlated with poor prognosis such as prostate cancer, breast cancer, myeloma, hepatocellular carcinoma and gastric cancer[37]. Mutations of the Y641 residue within the catalytic SET domain of EZH2 occur in 22% of diffuse large B-cell lymphomas (DLBCLs) and follicular lymphomas (FL)[38, 39], and 8%–24% of non-Hodgkin lymphomas (NHL)[40]. Homology modeling[41, 42] and the solved apo-structure of the EZH2 SET domain[43, 44] have disclosed Y641 as a key amino acid for substrate specificity. Mutations of Y641 into other smaller amino acids, such as phenylalanine (F), serine (S), histidine (H) and cysteine (C) resulted in changes in pocket dimensions, as well as hydrogen bonding, which allowed the free rotation of H3K27me2 and subsequent tri-methylation to H3K27me3 (a transcriptionally repressive mark) and led to repression of key tumor suppressor genes[45, 46]. Therefore, EZH2 and PRC2 have been proposed as attractive drug targets for cancer therapy, which has inspired several pharmaceutical companies to launch high-throughput screening campaigns to discover inhibitors of EZH2.

Several selective EZH2/1 inhibitors have been reported, which could be divided into 3 series according to their different structures: pyridone-indazole scaffold (EPZ005687, UNC1999, and GSK343), pyridone-indole scaffold (GSK126 and EI1), and pyridone-phenyl scaffold (EPZ006088 and EPZ6438). EPZ005687 was the first small molecule reported by Epizyme in 2016. Modeling of EPZ005687 indicated that the amide group joining pyridone with a methyl group adjacent to the amide providing the possibility of steric-directing effects both on the amide and aniline. EPZ6438 (tazemetostat) was thus discovered with THP substituted on the aniline core. EPZ6438 dose-dependently inhibited H3K27Me3 levels and cell proliferation in human lymphoma cell lines including EZH2WT and EZH2 mutants (A682 and Y646). Further in vivo assays in mice showed low clearance and desirable bioavailability, which led to clinical trials in patients with lymphoma (DLBCL and FL) and INI1-deficient solid tumors[51].

**SMYD2**

SMYD2, a SET and MYND domain containing HKMT, methylates H2B, H3, H4[52, 53], and other non-histone substrates, including retinoblastoma tumor suppressor RbK860 and RbK810[54] as well as tumor suppressors p53K370[55] and HSP90[56]. SMYD2 is highly expressed in 75% of esophageal squamous cell carcinomas (ESCCs)[57] and 95% of pediatric acute lymphoblastic leukemias[58] with poor survival. All of these characteristics point to its potential as a drug target to treat cancers. Several small molecule inhibitors have been developed to investigate the roles of SMYD2 in carcinoma and other biological processes. LLY-507[58] was disclosed as a selective, substrate-competitive inhibitor for SMYD2 with more than 100-fold selectivity over other HMTs and non-HMTs, including its homolog SMYD3. Cell-based assays showed that LLY-507 dose-dependently inhibited the expression of p53K370me1 in U2OS and KYSE-150 cells (ESCC cell lines) and the proliferation of ESCC, HCC and breast cancer cells. However, no obvious changes were observed in the global histone methylation levels using mass spectrometry-based proteomics, suggesting that SMYD2 is mainly present in the cytoplasm. Two other inhibitors, AZ505 and A-893, have also been reported[59, 60]. AZ505 and A-893 have similar structures except for one hydroxy group translocating from the benzoxazinone in AZ505 to the linker in A-893. Both of these inhibitors were shown to be selective, substrate-competitive SMYD2 inhibitors. Cell-based assays indicated that these two compounds reduced the expression levels of p53K370me1 in human A549 lung carcinoma cells. The co-crystal structure of SMYD2 with AZ505/A-893 suggested that two hydrophobic pockets are present: a primary pocket occupied by the cyclohexyl group and a secondary pocket occupied by the dichlorophenyl moiety, with the benzoxazinone group occupying the lysine-binding channel. An additional hydrogen bond between the benzylic alcohol and Y240 was formed in the co-crystal structure of SMYD2 with A-893, which contributes to the increased potency of A-893 compared to AZ505 (>80-fold).

...
Conclusion
The human histone methyltransferases (HMTs) are a large class of enzymes (>50), many of which are associated with cell differentiation, gene regulation and DNA recombination. Overexpression of HMTs has been linked to a variety of human malignancies. Owing to their common characteristics in chemical catalytic reactions, HMTs are likely to be tractable as targets for drug discovery. At this point, several potent small molecules have been discovered and show inhibitory activities in vitro and in vivo on various cancer cells. Such inhibitors have been used either as chemical probes to study enzyme functions or as candidates for drug development. Although histone methylation has been studied extensively, investigation of non-histone methylation is still in its infancy, which calls for further systematic research.

Acknowledgements
We gratefully acknowledge the financial support from the National Health and Family Planning Commission (2012ZX09304-011, 2013ZX09401003-005, 2013ZX09507001, 2013ZX09507-002, and 2014ZX09507002-001), the National Natural Science Foundation of China (21302202), Shanghai Science and Technology Development Fund (15DZ2291600), and the Thousand Talents Program in China.

References
1 Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol 2008; 4: 590–7.
2 Keppeler BR, Archer TK. Chromatin-modifying enzymes as therapeutic targets - Part 1. Expert Opin Ther Targets 2008; 12: 1301–12.
3 Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683–92.
4 Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009; 9: 91–105.
5 Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355–67.
6 Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007; 14: 1008–16.
7 Allfrey VG, Mirskey AE. Structural modifications of histones and their possible role in the regulation of RNA synthesis. Science 1964; 144: 559.
8 Murray K. The occurrence of epsilon-N-methyl lysine in histones. Biochemistry 1964; 3: 10–5.
9 Shi Y, Lan F, Matson C, Mulligan PJ, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941–53.
10 Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med 2005; 5: 77–86.
11 Cantoni GL. Biological methylation: selected aspects. Annu Rev Biochem 1975; 44: 435–51.
12 Wu JC, Santi DV. Kinetic and catalytic mechanism of Hhal methyltransferase. J Biol Chem 1987; 262: 4778–86.
13 Mandaviya PR, Stolik L, Heil SG. Homocysteine and DNA methylation: a review of animal and human literature. Mol Genet Metab 2014; 113: 243–52.
14 Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Disc 2009; 8: 724–32.
15 Kagan RM, Clarke S. Widespread occurrence of 3 sequence motifs in diverse S-adenosylmethionine-dependent methyltransferases suggests a common structure for these enzymes. Arch Biochem Biophys 1994; 310: 417–27.
16 Cheng X, Collins RE, Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu Rev Biophys Biomol Struct 2005; 34: 267–94.
17 Min J, Feng Q, Li Z, Zhang Y, Xu RM. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003; 112: 711–23.
18 Trievel RC, Flynn EM, Houtz RL, Hurley JH. Mechanism of multiple lysine methylation by the SET domain enzyme Rubisco LSMT. Nat Struct Biol 2003; 10: 545–52.
19 Anglin JL, Deng L, Yao Y, Cai G, Liu Z, Jiang H, et al. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem 2012; 55: 8066–74.
20 Stulemeijer U, De Vos D, van Harten K, Joshi OK, Blomberg O, van Welsum T, et al. Dot1 histone methyltransferases share a distributive mechanism but have highly diverged catalytic properties. Sci Rep 2015; 5: 9824.
21 Yao Y, Chen PH, Diao JH, Cheng G, Deng L, Anglin JL, et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc 2011; 133: 16746–9.
22 Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53–65.
23 Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122: 1017–25.
24 Sampath SC, Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbrauker I, et al. Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell 2007; 27: 596–608.
25 Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, et al. G9a and GLP methylate lysine 373 in the tumor suppressor p53. J Biol Chem 2010; 285: 9636–41.
26 Inagawa M, Nakajima K, Makino T, Ogawa S, Kojima M, Ito S, et al. Histone H3 lysine 9 methyltransferases, G9a and GLP are essential for cardiac morphogenesis. Mech Dev 2013; 130: 519–31.
27 Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011; 25: 781–8.
28 Artal-Martinez de Narvajas A, Gomez TS, Zhang JS, Mann AO, Taoda Y, Gorman JA, et al. Epigenetic regulation of autophagy by the methyltransferase G9a. Mol Cell Biol 2013; 33: 3983–93.
29 Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, et al. G9a and GLP methylate lysine 373 in the tumor suppressor p53. J Biol Chem 2010; 285: 9636–41.
30 Renneville A, Van Galen P, Canver MC, Conkey M, Krill-Burger JM, Dorfman DM, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood 2015; 126: 1930–9.
31 Kubeck S, O’Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodorou ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25: 473–81.
32 Chang YQ, Zhang X, Horton JR, Upadhay AK, Spannhoff A, Liu J, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 2009; 16: 312–7.
33 Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allahi-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2012; 7: 566–74.
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxyquinazolines. J Med Chem 2011; 54: 6139–50.

Devkota K, Lohse B, Liu Q, Wang MW, Stuerd K, Berthelsen J, et al. Analogues of the natural product sinfungin as inhibitors of EHMT1 and EHMT2. ACS Med Chem Lett 2014; 5: 293–7.

Marguieron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, et al. EzH1 and EzH2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32: 503–18.

Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21–9.

Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–5.

McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012; 109: 2989–94.

Knutson SK, Wigle TJ, Warholic NM, Snejenger CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890–6.

McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012; 109: 2989–94.

Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451–9.

Antonyamy S, Condon B, Druzina Z, Bonanno JB, Gheyi T, Zhang F, et al. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS One 2013; 8: e84147.

Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS One 2013; 8: e83737.

Kuntz KW, Campbell JE, Keilhack H, Pollock RM, Knutson SK, Porter-Scott M, et al. The importance of being Me: magic methyls, methyltransferase inhibitors, and the discovery of Tazemetostat. J Med Chem 2016; 59: 1556–64.

Brown MA, Sims RJ 3rd, Gottlieb PD, Tucker PW. Identification and characterization of Smyd2: a split SET/MYND-domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 2006; 5: 26.

Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figgey D. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics 2008; 7: 560–72.

Saddic LA, West LE, Aslanian A, Yates JR 3rd, Rubin SM, Gozani O, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 2010; 285: 37733–40.

Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006; 444: 629–32.

Nguyen H, Allali-Hassani A, Antonyamy S, Chang S, Chen LH, Curtis C, et al. LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2. J Biol Chem 2015; 290: 13641–53.

Komatsu S, Imoto I, Tsudo H, Kozaki KI, Muramatsu T, Shimada Y, et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009; 30: 1139–46.

Sakamoto LH, Andrade RV, Felipe MS, Motoyama AB, Pittella Silva F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk Res 2014; 38: 496–502.

Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 2011; 19: 1262–73.

Sweis RF, Wang Z, Algire M, Arrowsmih CH, Brown PJ, Chiang GG, et al. Discovery of A-893, a new cell-active benzoxazinone inhibitor of lysine methyltransferase SMYD2. ACS Med Chem Lett 2015; 6: 695–700.